CEBPB knockdown sensitizes nasopharyngeal carcinoma cells to cisplatin by promoting the expression of serine protease inhibitor Kazal-type 5
In conclusion, CEBPB silencing promoted chemoresistance of NPC cells via activating SPINK5, signifying that targeting CEBPB was a new approach to enhance the chemotherapy efficacy in NPC.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Pre-Clinical Reports Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Databases & Libraries | Genetics | Head and Neck Cancer | HNSCC | Nasopharyngeal Cancer | Skin Cancer | Squamous Cell Carcinoma | Websites